Health ❯ Healthcare ❯ Pharmaceuticals ❯ Clinical Trials

Drug Development

Novo’s Triple-Hormone Obesity Drug UBT251 Hits 19.7% Mean Weight Loss in China Phase 2

UBT251 targets GLP‑1, GIP plus glucagon for a mechanistically distinct approach to weight management.

Vistagen Faces Federal Securities Class Action After Fasedienol Phase 3 Failure

GLP-1 Boom Hits a Crossroads as States Cut Coverage and Next‑Gen Drugs Advance

Jasper Therapeutics Investors Face Lead Plaintiff Deadline in Securities Class Action

Regeneron’s Garetosmab Slashes New Bone Lesions in FOP Phase 3, U.S. Filing Planned This Year

Maze Therapeutics Reports Strong Phase 1 Signal for MZE782, Announces $150 Million Private Placement